A randomized double-blind placebo-controlled study of ALPN-101 in systemic lupus erythematosus.

Go Back to All Clinical Trials

A randomized double-blind placebo-controlled study of ALPN-101 in systemic lupus erythematosus.

Brief description of study

Subjects will be evaluated during a screening period of 42 days. Screening laboratory evaluations and disease activity assessments will be performed by the Investigator and reviewed by the sponsor to determine eligibility. Subjects will return for the Baseline visit to undergo assessment and confirmation of disease activity by the Investigator. Subjects who are eligible will be randomized to receive blinded study drug every 2 weeks for a total of 12 doses of 3mg/kg ALPN-101 or placebo.

Clinical Study Identifier: s20-01776

ClinicalTrials.gov Identifier: NCT04835441

Principal Investigator: David H. Goddard.

Other Investigators: Jennifer Hill, Andres M. Piatti, Lauren E. Wong.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Clinical Research Studies